CliffBio
small molecule

TOPIRAMATE

TOPIRAMATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameTOPIRAMATE
Active ingredientTOPIRAMATE
Strength200MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2009
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TOPIRAMATE patent cliff — loss of exclusivity — | CliffBio